Characterization of interleukin-1 receptor-associated kinase in normal and endotoxin-tolerant cells

被引:213
|
作者
Li, LW [1 ]
Cousart, S [1 ]
Hu, J [1 ]
McCall, CE [1 ]
机构
[1] Wake Forest Univ, Sch Med, Dept Med, Infect Dis Sect, Winston Salem, NC 27157 USA
关键词
D O I
10.1074/jbc.M001950200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Interleukin-1 receptor-associated kinase (IRAK), a signal transducer for interleukin-1, has also been suggested to participate in the Toll-like receptor-mediated innate immune response to bacterial endotoxin Lipopolysaccharide (LPS). Using the human promonocytic THP-1 cell line, we demonstrated that the endogenous IRAK is quickly activated in response to bacterial LPS stimulation, as measured by its in vitro kinase activity toward myelin basic protein. LPS also triggers the association of IRAK with MyD88, the adaptor protein linking IRAK to the Toll-like receptor/interleukin-1 beta receptor intracellular domain. Macrophage cells with prolonged LPS treatment become tolerant to additional dose of LPS and no longer express inflammatory cytokines, Endotoxin tolerance is a common phenomenon observed in blood from sepsis patients. We observed for the first time that the quantity of IRAK is greatly reduced in LPS-tolerant THP-1 cells, and its activity no longer responds to further LPS challenge. In addition, IRAK does not associate with MyD88 in the tolerant cells. Furthermore, application of AG126, a putative tyrosine kinase inhibitor, can substantially alleviate the LPS-induced cytokine gene expression and can also decrease IRAK level and activity. Our study indicates that IRAK is essential for LPS-mediated signaling and that cells may develop endotoxin tolerance by down-regulating IRAK.
引用
收藏
页码:23340 / 23345
页数:6
相关论文
共 50 条
  • [1] Interleukin-1β expression after inhibition of protein phosphatases in endotoxin-tolerant cells
    Yoza, BK
    Wells, JD
    McCall, CE
    CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 1998, 5 (03) : 281 - 287
  • [2] Tolerance and sensitization to endotoxin in Kupffer cells caused by acute ethanol involve interleukin-1 receptor-associated kinase
    Yamashina, S
    Wheeler, MD
    Rusyn, I
    Ikejima, K
    Sato, N
    Thurman, RG
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2000, 277 (03) : 686 - 690
  • [3] ROLE OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 1 IN ENDOTHELIAL CELLS INJURY AND REPAIR
    Miao, Jiaxing
    Zhao, Jing
    Zhao, Yutong
    Baoyinna, Baoyinna
    Shaheen, Nargis
    Kasey, Lee
    Xi, Xiaoqing
    Xia, Boyu
    JOURNAL OF INVESTIGATIVE MEDICINE, 2024, 72 (07) : 142 - 145
  • [4] Interleukin-1 receptor-associated kinase-1: More evidence
    Moretti, Eugene W.
    CRITICAL CARE MEDICINE, 2010, 38 (12) : 2410 - 2411
  • [5] The Role of interleukin-1 receptor-associated kinase 4 in drug addiction
    Wu, Ruyan
    Liu, Jian-Feng
    Vu, Jimmy
    Johnson, Bernard
    Li, Jun-Xu
    FASEB JOURNAL, 2019, 33
  • [6] The Role of Interleukin-1 Receptor-Associated Kinase 4 in Opioid Addiction
    Wu, Ruyan
    Liu, Jianfeng
    Vu, Jimmy
    Johnson, Bernard
    Li, Jun-Xu
    NEUROPSYCHOPHARMACOLOGY, 2019, 44 (SUPPL 1) : 501 - 501
  • [7] Interleukin-1 Receptor-Associated Kinase 4 Deficiency in a Greek Teenager
    Karananou, Panagiota
    Alataki, Anastasia
    Papadopoulou-Alataki, Efimia
    CASE REPORTS IN IMMUNOLOGY, 2020, 2020
  • [8] The Role of Interleukin-1 Receptor-Associated Kinase 4 in Drug Addiction
    李俊旭
    神经药理学报, 2019, 9(Z1) (Z1) : 19 - 20
  • [9] Targeting interleukin-1 receptor-associated kinase 1 for human hepatocellular carcinoma
    Ning Li
    Jinhua Jiang
    Jing Fu
    Ting Yu
    Bibo Wang
    Wenhao Qin
    An Xu
    Mengchao Wu
    Yao Chen
    Hongyang Wang
    Journal of Experimental & Clinical Cancer Research, 35
  • [10] Targeting interleukin-1 receptor-associated kinase 1 for human hepatocellular carcinoma
    Li, Ning
    Jiang, Jinhua
    Fu, Jing
    Yu, Ting
    Wang, Bibo
    Qin, Wenhao
    Xu, An
    Wu, Mengchao
    Chen, Yao
    Wang, Hongyang
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2016, 35